Acarbose and acetaminophen: A dangerous combination?

✍ Scribed by Hans J. Ahr; Ernst Bomhard; Ulrich Schmidt; Gerhard Schlüter

• Book ID: 102245847
• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 45 KB
• Volume: 30
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.510300127

✦ Synopsis

entered the trial in 1989. Therefore, there were only 4 untreated and 7 treated patients at the end of ''10 years of follow-up.'' These numbers are indeed small, but those at the end of 8 years or less are adequate (Table 1). Furthermore, the opportunity for relatively long-term follow-up of this number of untreated patients might be possible only in countries like Taiwan in which the only licensed drug is expensive and not covered by health insurance.

As to patients with HBV/HCV dual infection, studies have shown that such patients react differently, including response to interferon therapy, than patients with chronic HBV infec-tion alone. 4 It seems reasonable to exclude patients with dual infection from the analysis.